Annex 
Conditions or restrictions with regard to the safe and effective use of the 
medicinal product to be implemented by the member states 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions  or  restrictions  with  regard  to  the  safe  and 
effective  use  of  the  medicinal  product  to  be  implemented 
by the member states 
The Member States shall ensure that the following conditions or restrictions with regard to the safe 
and effective use of the medicinal product described below are implemented: 
-  The  MAH  shall  provide  an  educational  pack  for  each  therapeutic  indication,  targeting  all 
physicians who are expected to prescribe/use Pradaxa. This educational pack is aimed at increasing 
awareness  about  the  potential  risk  of  bleeding  during  treatment  with  Pradaxa  and  providing 
guidance on how to manage that risk. 
-  The  content  and  format  of  the  educational  material,  together  with  a  communication  plan,  is 
agreed with the MAH prior to distribution of the educational pack.   
-  The  educational  pack  must  be  available  for  distribution  for  both  therapeutic  indications  prior  to 
the launch of the new indication (prevention of stroke and systemic embolism in adult patients with 
nonvalvular atrial fibrillation with one or more risk factors) in the Member State. 
The physician educational pack should contain: 
- The Summary of Product Characteristics 
- Prescriber Guide 
- Patient Alert Cards  
The Prescriber Guide should contain the following key safety messages: 
- Details of populations potentially at higher risk of bleeding  
- Recommendation not to use Pradaxa in patients with prosthetic heart valves 
- Recommendation for kidney function measurement 
- Recommendations for dose reduction in at risk populations 
- Management of overdose situations  
- The use of coagulation tests and their interpretation 
- That all patients should be provided with a Patient alert card and be counselled about: 
o  Signs or symptoms of bleeding and when to seek attention from a health care provider. 
o 
Importance of treatment compliance  
o  Necessity to carry the Patient alert card with them at all times  
o  The need to inform Health Care Professionals that they are taking Pradaxa if they need 
to have any surgery or invasive procedure. 
- An instruction how to take Pradaxa 
The Patient alert card should contain the following key safety messages: 
o  Signs or symptoms of bleeding and when to seek attention from a health care provider. 
o 
Importance of treatment compliance  
 
 
o  Necessity to carry the Patient alert card with them at all times  
o  The need to inform Health Care Professionals that they are taking Pradaxa if they need to 
have any surgery or invasive procedure. 
o  An instruction how to take Pradaxa 
 
